盐酸非索非那定(Fexofenadine Hydrochloride) - 药物靶点：H1 receptor_在研适应症：慢性荨麻疹，瘙痒，过敏性鼻炎_专利_临床

概要

基本信息

简介非索非那定于1996年3月获得FDA批准，是一种令人费解的小分子药物，可作为H1受体拮抗剂。该药物阻碍组胺在H1受体的作用，减少呼吸超敏反应，荨麻疹，皮炎，瘙痒和其他皮肤病。非索非那定主要用于这些疾病，有助于缓解其症状。赛诺菲是非索非那定的神秘鼻祖组织，已在临床上得到广泛应用。尽管其广泛使用，但这种药物的具体作用机制尚不清楚。然而，非索非那定是治疗过敏和相关疾病的重要武器，尽管它可能导致嗜睡和口干以及其他副作用。非索非那定副作用的可变性和不精确的作用方式突出了进一步研究以充分理解药物作用机制的必要性。

药物类型

小分子化药

别名

Allegra 5%、Fexofenadine hydrochloride (JP17/USP)、Fexofenading Hydrochloride

+ [27]

靶点

H1 receptor

作用方式

拮抗剂

作用机制

H1 receptor拮抗剂(组胺H1受体拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Opella Healthcare Group SAS

植恩生物技术股份有限公司sanofi-aventis Healthcare Holdings Pty Ltd.

+ [11]

非在研机构

Sanofi

Chattem, Inc.

权益机构-

最高研发阶段批准上市

首次获批日期

英国 (1996-03-11),

季节性过敏性鼻炎

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C32H40ClNO4

InChIKeyRRJFVPUCXDGFJB-UHFFFAOYSA-N

CAS号153439-40-8

关联

104

项与盐酸非索非那定相关的临床试验

NCT05720455

/ Not yet recruiting临床4期

A Phase IV, Open Label, Clinical Trial to Assess Safety and Efficacy of Fexofenadine HCL + Pseudoephedrine HCL Fixed Dose Combination in Indian Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above (FAST Trial)

This is a single group, Phase IV clinical trial to assess the safety and effectiveness of Allegra® D. This study will be conducted in participants with allergic rhinitis who are 12 years of age and above. The individual study duration for each participant would be approximately 16 days (maximum of 13 days intervention + a 3-day post intervention observation). There would be 4 study visits in which the last visit can be done either telephonically or on site. Safety events would be captured for the entire study duration. In addition, the effectiveness of the study drug would be assessed using Nasal symptom score (NSS) and Total symptom score (TSS).

开始日期2025-06-06

申办/合作机构

Sanofi

CTR20251886

/ RecruitingN/A

盐酸非索非那定片在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验

主要目的：以药代动力学参数为终点指标，比较空腹和高脂餐后给药条件下，合肥合源药业有限公司生产的盐酸非索非那定片与OPELLA HEALTHCARE FRANCE SAS为持证商的盐酸非索非那定片（规格：180mg）在健康成年人群中吸收程度和速度的差异，对两制剂的生物等效性进行评价。次要目的：评价健康受试者在空腹和高脂餐后给药条件下口服受试制剂盐酸非索非那定片和参比制剂盐酸非索非那定片的安全性。

开始日期2025-05-30

申办/合作机构

合肥合源药业有限公司

CTRI/2025/03/082777

/ Not yet recruiting临床4期IIT

Comparison of efficacy, safety, and cost-effectiveness of levocetirizine, fexofenadine, and bilastine in treatment of allergic rhinitis: A randomized, open-label, parallel-group study - NIL

开始日期2025-04-15

申办/合作机构-

100 项与盐酸非索非那定相关的临床结果

登录后查看更多信息

100 项与盐酸非索非那定相关的转化医学

登录后查看更多信息

100 项与盐酸非索非那定相关的专利（医药）

登录后查看更多信息

2,415

项与盐酸非索非那定相关的文献（医药）

2025-07-01·Urology Practice

Effect of Antihistamine on Ureteral Stent–Related Symptoms: A Double-Blind Randomized Controlled Trial

Article

作者: Shah, Ojas ; Margolin, Ezra J. ; Chowdhury, Mahveesh ; Han, David S. ; Johnson, Jeffrey P. ; Schulster, Michael L. ; Movassaghi, Miyad ; Pingle, Srinath-Reddi ; Weiner, David M.

INTRODUCTION:

Given evidence of antihistamine's efficacy in bladder pain syndrome and renal colic, we evaluated the effect of antihistamine on ureteral stent-related symptoms.

METHODS:

We performed a double-blind, randomized controlled trial of adults undergoing unilateral ureteroscopy with stent placement for urolithiasis treatment. Coloplast Imajin silicone stents (Coloplast A/S, Humlebaek, Denmark) were used for all procedures. Alongside nonsteroidal anti-inflammatory medications for pain control, patients were randomly prescribed a 10-day course of either fexofenadine 180 mg oral daily (study arm) or placebo (control). The primary outcome was Ureteral Stent Symptoms Questionnaire urinary symptoms and pain scores with stent in situ immediately before stent removal; groups were compared using the Student t test. Higher scores represented increasing symptom severity.

RESULTS:

Of 73 patients (37 study arm, 36 control arm), mean age was 52 years old, and the majority were male (60%). Mean stone burden (10 mm) and median time to stent removal (9 days) were similar between groups. With stent in situ, there were no differences in urinary symptoms or pain scores between study and control groups (28 vs 29, P = .85 and 14 vs 17, P = .25); moreover, there were no differences between arms in any Ureteral Stent Symptoms Questionnaire domain at this timepoint (P > .05). There were no differences between study and control groups in postdischarge narcotic analgesia use (5% vs 14%, P = .26), total number of office phone calls (5 vs 9, P = .61), or total number of emergency department visits (2 vs 3, P = .67).

CONCLUSIONS:

Postoperative antihistamines were well tolerated but did not significantly reduce ureteral stent-related symptoms.

2025-07-01·JOURNAL OF HAZARDOUS MATERIALS

Association between organic micropollutants in tap water and human exposure and birth outcomes: Implications for environmental health in northern Puerto Rico

Article

作者: Kaeli, David ; Padilla, Ingrid Y ; Rich, Stephanie L ; Manjourides, Justin ; Alshawabkeh, Akram N ; Gao, Griffith ; Feng, Yinmei ; Rosario-Pabón, Zaira ; Helbling, Damian E ; Li, Guangyu ; Gu, April Z ; Vega, Carmen Velez ; Meeker, John D

The presence of micropollutants in Puerto Rico's tap water, potentially linked to nearby Superfund sites, was hypothesized to contribute to the region's higher preterm birth rate than the US mainland. This study analyzed the presence of 175 micropollutants in tap water samples collected from participant households and evaluated their association with human exposure using 14 oxidative stress and inflammation biomarkers in urine samples collected from pregnant participants, and further with the subsequent birth outcome information. Notably, three out of four oxidative stress biomarkers consistently showed negative correlations with five micropollutant categories, highlighting the oxidative stress induced by these contaminants. For the ten selected inflammation-related biomarkers, two showed positive yet not significant correlations with the five categories of micropollutants and, only one biomarker (MMP1), an inflammation biomarker whose down-regulation was associated with pre-mature birth implications, showed significant negative correlation with industrial chemicals and pesticides. Interestingly, the detected urinary phthalate metabolites in pregnant women could not be linked with the two parent phthalates found in the tap water, suggesting that the two phthalates in tap water may not be the primary source of phthalate exposure to human body. Furthermore, hormones in tap water showed significant moderate-to-strong negative correlations with birth outcomes, raising specific health concerns for pregnant women in northern Puerto Rico. This is the first study to investigate the association among a wider spectrum of tap water micropollutants with pregnancy exposure and birth outcome in Puerto Rico and provide insights into water quality and associated human health impacts.

2025-07-01·CLINICAL PHARMACOLOGY & THERAPEUTICS

Green Tea Catechins as Perpetrators of Drug Pharmacokinetic Interactions

Review

作者: McLachlan, Andrew J. ; Gross, Annette S. ; Kyriacou, Nicki M.

Green tea (Camellia sinensis) is a commonly consumed beverage or dietary supplement. As a natural product with a myriad of proposed health benefits, patients are likely to consume green tea while taking their medications unaware of its potential to interact with drugs and influence drug efficacy and safety. Catechins are the abundant polyphenolic compounds in green tea (e.g., (−)‐epigallocatechin‐3‐gallate), which are reported to influence determinants of drug pharmacokinetics, such as drug solubility and the activity of drug transporters and drug metabolizing enzymes. This review summarized the results of clinical studies investigating the influence of green tea catechins on the pharmacokinetics of clinically used medications. The majority of analyses (72%) reported significant decreases (by 18–99%) in systemic drug exposure with green tea consumption (atorvastatin, celiprolol, digoxin, fexofenadine, folic acid, lisinopril, nadolol, nintedanib, raloxifene, and rosuvastatin). One analysis (6%) reported a 50% increase in drug systemic exposure (sildenafil) and for 22% of analyses drug pharmacokinetics were not affected by green tea consumption (fluvastatin, pseudoephedrine, simvastatin, and tamoxifen). For most drugs reporting an interaction, green tea catechins were proposed to decrease intestinal drug absorption by inhibiting OATP uptake (particularly OATP1A2), enhancing P‐gp efflux activity or reducing drug solubility. Case reports have associated changes in drug pharmacokinetics with green tea consumption to changes in drug efficacy or safety (e.g., nadolol and erlotinib). These findings prompt the need for further research in relating evidence from existing literature to predict additional clinically important green tea–drug interactions and to provide appropriate recommendations for patients and clinicians.

90

项与盐酸非索非那定相关的新闻（医药）

2025-07-08

·健识局

济川药业1.1类中药创新药小儿便通颗粒上市申请获受理

近日，济川药业收到国家药品监督管理局签发的1.1类中药创新药小儿便通颗粒申报上市许可的《受理通知书》。小儿便通颗粒来源于名医验方，具有健脾和胃、行气导滞的功效，用于小儿便秘，中医辨证属食积证者。根据公开信息，中国境内（不包括港澳台地区）暂无与其处方一致的药品上市或注册申报信息。该产品有望成为《小儿便秘中药新药临床研发技术指导原则（试行）》（2024年）发布后的首个用于小儿便秘的中药1.1类儿童专用药。作为国内拥有儿科品种、剂型最多的制药企业之一，济川药业深耕儿科优势领域多年，先后培育了蒲地蓝消炎口服液、同贝®小儿豉翘清热颗粒、健胃消食口服液、黄龙止咳颗粒、盛雪元®蛋白琥珀酸铁口服溶液等品牌产品。同时，公司不断加强上市品种的二次开发、中药新药和高端化药研发，获批了新版《药品注册管理办法》实施以来首个中药改良型新药金同贝®小儿豉翘清热糖浆，成为了国内首家获批敏菲乐®盐酸非索非那定干混悬剂和贝罗南®小儿法罗培南钠颗粒的药企，提升了儿科领域的核心竞争力。此外，济川药业以商业拓展赋能外延式扩张，形成了自主创新和合作研发相结合的研发体系，联合征祥医药开发的流感1类创新药玛硒洛沙韦片，是一款具有全球自主知识产权的新一代靶向流感病毒RNA聚合酶PA抑制剂，全疗程一次用药，上市申请已获国家药监局药品审评中心受理；与天境生物合作开发1类创新药融合蛋白型长效生长激素的生物制品上市申请已获得国家药品监督管理局受理，每周一次给药，该创新疗法有望为儿童生长激素缺乏症患者带来有效且便捷的治疗方案。未来，济川药业将继续以“共创幸福精彩的生命体验”为愿景，秉承“引领前沿、创新精品”的研发理念，紧跟医药市场变化，从患者用药需求出发，聚焦中长期发展战略，以科研创新驱动企业高质量、可持续发展，履行好上市医药企业应有的社会责任，为大众健康护航。运营丨晨曦中医馆化身骗保“流水线”，两年诈骗医保基金超1200万元！总裁离职后，知名药企办公室遭围堵新事丨阿斯利康计划从英国退市

2025-07-08

·米内网

【重磅】济川药业创新研发新突破！1类新药小儿便通颗粒上市申请获受理

精彩内容近日，济川药业收到国家药监局签发的1.1类中药创新药小儿便通颗粒申报上市许可的《受理通知书》。资料显示，小儿便通颗粒来源于名医验方，具有健脾和胃、行气导滞的功效，用于小儿便秘，中医辨证属食积证者。来源：CDE官网根据公开信息，中国境内（不包括港澳台地区）暂无与其处方一致的药品上市或注册申报信息，小儿便通颗粒有望成为《小儿便秘中药新药临床研发技术指导原则（试行）》（2024年）发布后的首个用于小儿便秘的中药1.1类新药。作为国内拥有儿科品种、剂型最多的制药企业之一，济川药业深耕儿科优势领域多年，先后培育了蒲地蓝消炎口服液、同贝®小儿豉翘清热颗粒、健胃消食口服液、黄龙止咳颗粒、盛雪元®蛋白琥珀酸铁口服溶液等品牌产品。同时，公司不断加强上市品种的二次开发、中药新药和高端化药研发，一举拿下新版《药品注册管理办法》实施以来首个中药改良型新药金同贝®小儿豉翘清热糖浆；成为国内首家获批敏菲乐®盐酸非索非那定干混悬剂和贝罗南®小儿法罗培南钠颗粒的药企，进一步提升了儿科领域的核心竞争力。此外，济川药业以商业拓展赋能外延式扩张，形成了自主创新和合作研发相结合的研发体系。公司联合征祥医药开发出流感1类创新药玛硒洛沙韦片，该新药是一款具有全球自主知识产权的新一代靶向流感病毒RNA聚合酶PA抑制剂，全疗程仅需用药一次，其上市申请已获CDE受理，目前在审评审批阶段；与天境生物合作开发的1类创新药融合蛋白型长效生长激素的生物制品上市申请也已获CDE受理，每周给药一次，该创新疗法有望为儿童生长激素缺乏症患者带来有效且便捷的治疗方案。据悉，济川药业将继续以“共创幸福精彩的生命体验”为愿景，秉承“引领前沿、创新精品”的研发理念，紧跟医药市场变化，从患者用药需求出发，聚焦中长期发展战略，以科研创新驱动企业高质量、可持续发展，履行好上市医药企业应有的社会责任，为大众健康护航。免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

2025-07-06

·ioncology

乳腺癌对德曲妥珠单抗耐药怎么办

点击蓝字，关注我们近年来，抗体缀合药物德曲妥珠单抗已经成为治疗HER2表达乳腺癌的大杀器，不论HER2高表达、低表达还是超低表达。不过，仍有大约25%至50%的患者对此药完全无效或者继发耐药。2025年6月27日，英国《自然》旗下《自然癌症》在线发表美国梅奥（妙佑）医学中心、匹兹堡大学、NSABP基金会、哈佛大学医学院达纳法伯癌症研究所、康奈尔大学、佛罗里达大学、中国清华大学、芬兰赫尔辛基大学的研究报告，发现这些对德曲妥珠单抗耐药的HER2阳性乳腺癌能够表达比普通HER2短一截的p95HER2引起免疫逃逸，从而促进肿瘤生长并产生德曲妥珠单抗耐药，问世十多年来命运坎坷的奈拉替尼对此有效。这源于p95HER2具有促进乳腺癌细胞表达程序性死亡配体PD-L1让人体免疫细胞进入自杀程序并分泌白细胞介素IL-6等免疫抑制介质的独特能力。对于临床前模型，这可削弱德曲妥珠单抗的疗效，因为其完全疗效依赖于对细胞死亡的免疫原反应。重要的是，该研究发现奈拉替尼能够有效引导蛋白酶体降解p95HER2，从而减轻其免疫抑制作用。该研究对此概念进行验证，表明奈拉替尼±p95HER2下游介质靶向药物可以恢复人体抗肿瘤免疫力和德曲妥珠单抗的疗效。因此，该研究结果表明，p95HER2能够引起HER2阳性乳腺癌的免疫抑制程序和耐药机制，奈拉替尼可以靶向p95HER2，对于改善抗体缀合药物或者肿瘤免疫治疗药物的疗效具有潜在价值。Nat Cancer. 2025 Jun 27. IF: 28.5p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2(+) breast cancer that limits trastuzumab deruxtecan efficacy.Hu D, Lyu X, Li Z, Ekambaram P, Dongre A, Freeman T, Joy M, Atkinson JM, Brown DD, Cai Z, Carleton NM, Crentsil HE, Little J 4th, Kemp F, Klei LR, Beecher M, Sperinde J, Huang W, Joensuu H, Srinivasan A, Pogue-Geile KL, Wang Y, Feng H, Eli LD, Lalani AS, Zou J, Tseng GC, Bruno TC, Lee AV, Oesterreich S, Wolmark N, Allegra CJ, Jacobs SA, McAllister-Lucas LM, Lucas PC.Mayo Clinic, Rochester, MN, USA; University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; UPMC Hillman Cancer Center, Pittsburgh, PA, USA; BlueSphere Bio, Pittsburgh, PA, USA; NSABP Foundation, Inc., Pittsburgh, PA, USA; University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA; School of Medicine, Tsinghua University, Beijing, China; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Cornell University, Ithaca, NY, USA; Monogram Biosciences, Laboratory Corporation of America Holdings, South San Francisco, CA, USA; Puma Biotechnology, Los Angeles, CA, USA; University of Florida Health, Gainesville, FL, USA; Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.Resistance to human epidermal growth factor receptor 2 (HER2)-targeted therapies and immuno-oncology agents poses a major challenge in treating HER2-positive breast cancer. Here we demonstrate that p95HER2, a truncated form of HER2, drives immune evasion in HER2-positive female breast cancer, enhancing tumor growth and conferring therapy resistance. This stems from the unique ability of p95HER2 to promote cancer cell-intrinsic programmed death ligand 1 expression and secretion of immunosuppressive mediators including interleukin 6. In preclinical models, this impairs the efficacy of trastuzumab deruxtecan, a HER2-directed antibody-drug conjugate (ADC) that relies on immunogenic responses to cell death for full efficacy. Importantly, we find that neratinib potently directs proteasomal degradation of p95HER2, relieving its immunosuppressive effects, and provide proof of concept that neratinib and/or agents targeting p95HER2 downstream mediators can restore antitumor immunity and trastuzumab deruxtecan efficacy. This study reveals a p95HER2-specific therapy resistance mechanism in HER2-positive female breast cancer and highlights the potential value of targeting p95HER2 to improve outcomes with ADCs or immuno-oncology agents.PMID: 40579589DOI: 10.1038/s43018-025-00969-4（来源：SIBCS）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

免疫疗法临床研究

100 项与盐酸非索非那定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00671	盐酸非索非那定	R06AX26	DBSALT001227

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
呼吸道过敏	美国	Chattem, Inc.	2011-01-24
瘙痒	日本	Sanofi KK	2002-04-15
慢性荨麻疹	美国	Chattem, Inc.	2000-02-25
过敏性鼻炎	韩国	Handok, Inc.	1998-05-04
荨麻疹	澳大利亚	Sanofi /Consumer Healthcare Brands/	1997-01-10
季节性过敏性鼻炎	英国	Aventis Pharma Ltd.	1996-03-11

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
特应性皮炎	临床3期	日本	Sanofi	2010-11-01
常年性鼻炎	临床3期	日本	Sanofi	2010-10-01
常年性变应性鼻炎	临床3期	日本	Sanofi	2010-10-01
持续性哮喘	临床3期	美国	Sanofi	2002-02-01
持续性哮喘	临床3期	哥斯达黎加	Sanofi	2002-02-01
持续性哮喘	临床3期	危地马拉	Sanofi	2002-02-01
持续性哮喘	临床3期	匈牙利	Sanofi	2002-02-01
持续性哮喘	临床3期	墨西哥	Sanofi	2002-02-01
持续性哮喘	临床3期	波兰	Sanofi	2002-02-01
持续性哮喘	临床3期	俄罗斯	Sanofi	2002-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05692154 (FEXPRESAR, CTgov)	临床3期	季节性过敏性鼻炎	95	Fexofenadine (Arm A (Active-active))	蓋夢鬱鑰憲壓網簾齋衊(襯蓋遞壓鑰夢鏇鏇鹽憲) = 觸壓積積餘鹹壓鑰觸積糧選遞膚顧鑰鬱壓憲鹹 (襯齋糧蓋餘選鏇選衊壓, 9.090) 更多	-	2024-05-16
				Placebo (Arm B (Placebo-active))	蓋夢鬱鑰憲壓網簾齋衊(襯蓋遞壓鑰夢鏇鏇鹽憲) = 鹹夢鹽襯簾窪廠齋構憲糧選遞膚顧鑰鬱壓憲鹹 (襯齋糧蓋餘選鏇選衊壓, 10.431) 更多
NCT03994731 (MIRROR RCT \| MIRROR, CTgov)	临床4期	痛风	152	gout flare prophylaxis regimen+acetaminophen+methylprednisolone+fexofenadine+folic acid+methotrexate+Pegloticase (Pegloticase + MTX)	簾網蓋遞齋觸築觸糧鹹 = 觸製觸夢鑰積願顧遞選窪構蓋膚鏇網製鬱夢艱 (壓齋壓鏇鬱醖鏇淵積鬱, 積夢遞繭願糧蓋顧糧積 ~ 遞鏇醖壓夢製醖顧選廠) 更多	-	2022-05-16
				placebo+acetaminophen+methylprednisolone+fexofenadine+folic acid+methotrexate+Pegloticase (Pegloticase + Placebo)	簾網蓋遞齋觸築觸糧鹹 = 範蓋簾選顧壓鬱齋積簾窪構蓋膚鏇網製鬱夢艱 (壓齋壓鏇鬱醖鏇淵積鬱, 衊憲廠範鬱製繭窪餘窪 ~ 觸積鏇襯顧積鏇構憲鹹) 更多
UEGW2018	N/A	肥大细胞激活障碍	-	Ketotifen	鹹選鬱觸糧糧構襯壓醖(積積願遞選獵觸蓋製獵) = 觸壓鏇艱繭醖夢艱繭憲製顧鏇衊衊齋壓願醖襯 (壓憲獵餘觸淵簾鏇窪範 )	-	2018-10-01
				Fexofenadine	鹹選鬱觸糧糧構襯壓醖(積積願遞選獵觸蓋製獵) = 顧製鏇鑰繭鑰襯鬱衊範製顧鏇衊衊齋壓願醖襯 (壓憲獵餘觸淵簾鏇窪範 )
NCT01469234 (P08712, CTgov)	临床4期	季节性过敏性鼻炎	255	placebo to fexofenadine+loratadine (Loratadine)	齋鹽鬱衊醖簾獵壓鏇選(醖鹹醖衊鹹膚艱繭齋夢) = 膚餘遞製餘鬱顧襯鹽遞艱獵觸淵夢鏇襯襯淵壓 (繭鏇範衊鏇壓鹹醖簾鹹, 4.51) 更多	-	2013-03-22
				placebo to loratadine+fexofenadine (Fexofenadine)	齋鹽鬱衊醖簾獵壓鏇選(醖鹹醖衊鹹膚艱繭齋夢) = 觸夢衊構憲簾糧壓憲製艱獵觸淵夢鏇襯襯淵壓 (繭鏇範衊鏇壓鹹醖簾鹹, 4.86) 更多
NCT01526213 (CTgov)	N/A	-	18	furanocoumarin+fexofenadine (Water)	繭齋繭膚艱蓋構窪遞蓋(憲鬱衊衊淵鬱襯遞淵獵) = 築餘餘蓋鬱遞鬱憲願襯築淵淵積鏇糧網膚選繭 (構觸鹹鏇積獵範憲鹹鏇, 積鹹製製蓋醖鏇糧遞獵 ~ 窪簾選糧餘鑰網淵醖糧) 更多	-	2013-02-04
				furanocoumarin+fexofenadine (Grapefruit Juice)	繭齋繭膚艱蓋構窪遞蓋(憲鬱衊衊淵鬱襯遞淵獵) = 艱繭襯鑰襯窪襯鹽鹽鬱築淵淵積鏇糧網膚選繭 (構觸鹹鏇積獵範憲鹹鏇, 廠廠築淵夢網構餘壓選 ~ 壓艱廠廠鑰願壓築膚鹽) 更多
ASCO2012	N/A	间质性肺疾病	145	Fexofenadine	鏇繭選積膚壓顧鏇製鏇(蓋觸壓窪範餘壓選蓋遞) = 鏇製顧齋鏇鹽廠糧蓋網壓鑰鏇淵餘襯鹽窪壓積 (獵壓鬱醖獵鬱顧製淵遞 ) 更多	-	2012-05-20
				No Fexofenadine	鏇繭選積膚壓顧鏇製鏇(蓋觸壓窪範餘壓選蓋遞) = 觸築網襯構齋窪鹽鑰顧壓鑰鏇淵餘襯鹽窪壓積 (獵壓鬱醖獵鬱顧製淵遞 ) 更多
NCT00835640 (CTgov)	临床1期	-	24	Fexofenadine Hydrochloride (Fexofenadine Hydrochloride)	範願鹽獵夢膚窪膚鏇憲(壓觸餘繭蓋選餘鬱築淵) = 夢構齋願鬱夢醖鬱鏇醖廠範築遞簾製獵夢積顧 (製獵齋淵壓膚膚遞積憲, 99.83) 更多	-	2009-08-04
				Allegra (Allegra®)	範願鹽獵夢膚窪膚鏇憲(壓觸餘繭蓋選餘鬱築淵) = 築築衊顧鹹鬱顧壓獵襯廠範築遞簾製獵夢積顧 (製獵齋淵壓膚膚遞積憲, 119.07) 更多
NCT00835276 (CTgov)	临床1期	-	60	Fexofenadine Hydrochloride (Fexofenadine Hydrochloride)	壓網廠膚鹹壓願衊觸顧(淵簾顧遞衊糧膚鏇鬱鹹) = 網艱範選遞憲鹽廠艱醖蓋壓築蓋蓋膚構選鏇壓 (鹹壓蓋鬱鹽願顧繭壓醖, 216.08) 更多	-	2009-08-04
				Allegra (Allegra®)	壓網廠膚鹹壓願衊觸顧(淵簾顧遞衊糧膚鏇鬱鹹) = 壓簾齋遞範鏇蓋衊觸簾蓋壓築蓋蓋膚構選鏇壓 (鹹壓蓋鬱鹽願顧繭壓醖, 204.3) 更多
AAAAI2007	N/A	过敏性鼻炎	-	Fexofenadine HCl 6 mg/mL Suspension	構淵餘遞艱製簾鬱糧範(範範範範鏇鹹鏇壓鬱窪) = Ten treatment-emergent adverse events (TEAEs) occurred in seven subjects. No serious, one moderate intensity (pyrexia) and nine mild intensity TEAEs were reported. All TEAEs resolved without sequelae. 憲顧願蓋鹹選糧顧簾範 (淵範簾餘憲膚襯醖鹹範 ) 更多	积极	2007-01-01
SFN2003	N/A	认知功能障碍	20	Fexofenadine (FEX)	餘築觸鹹觸膚繭願餘觸(繭顧鏇遞壓齋艱餘願壓) = 顧襯觸鬱餘顧積廠夢遞獵夢網糧膚構遞網鏇繭 (衊廠膚製鬱簾膚壓鬱襯 )	积极	2003-11-09
				Cetirizine (CET)	餘築觸鹹觸膚繭願餘觸(繭顧鏇遞壓齋艱餘願壓) = 醖鬱淵鹹網鹹鑰夢選襯獵夢網糧膚構遞網鏇繭 (衊廠膚製鬱簾膚壓鬱襯 )